Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan.
Cancer Med. 2024 May;13(9):e7242. doi: 10.1002/cam4.7242.
Following treatment of superficial esophageal squamous cell carcinoma (ESCC), surveillance for a second primary malignancy (SPM) is necessary. However, detailed evidence regarding the timing and prognosis of SPMs is insufficient. We aimed to clarify the details of SPMs and their effects on patient outcomes.
This retrospective, multicenter study involved 11 hospitals. Patients with superficial ESCC curatively resected using endoscopic submucosal dissection between May 2005 and December 2012, were included in this study.
The 5-year survival rate of 187 patients was 92.6% during a median follow-up duration of 96.8 months. Thirty-one patients died, 14 of whom died of SPMs. Compared to patients with SPMs detectable by esophagogastroduodenoscopy (EGD), patients with SPMs detectable only by modalities other than EGD had a significantly higher mortality rate (p < 0.001). Patients with second primary lung cancer (LC) had a high mortality rate (56.3%). Univariate and multivariate analyses showed that multiple Lugol-voiding lesions (LVLs) tended to be associated with SPMs (p = 0.077, hazard ratio [HR] 4.43, 95% confidence interval [CI]: 0.91-6.50), and metachronous ESCC was an independent risk factor for the incidence of second primary LC (p = 0.037, HR 3.51, 95% CI: 1.08-11.41).
SPMs that cannot be detected by EGD, such as LC, must be considered after the curative resection of ESCC. We suggest strict screening by both EGD and computed tomography for patients with multiple LVLs or metachronous ESCC to detect SPMs in their early stages.
治疗表浅性食管鳞状细胞癌(ESCC)后,需要对第二原发恶性肿瘤(SPM)进行监测。然而,有关 SPM 发生时间和预后的详细证据仍然不足。本研究旨在阐明 SPM 的细节及其对患者预后的影响。
这是一项回顾性多中心研究,涉及 11 家医院。研究纳入了 2005 年 5 月至 2012 年 12 月期间接受内镜黏膜下剥离术根治性切除的表浅性 ESCC 患者。
187 例患者的 5 年生存率为 92.6%,中位随访时间为 96.8 个月。31 例患者死亡,其中 14 例死于 SPM。与可通过食管胃十二指肠镜(EGD)检测到 SPM 的患者相比,仅通过 EGD 以外的方式检测到 SPM 的患者死亡率显著更高(p<0.001)。第二原发肺癌(LC)患者的死亡率较高(56.3%)。单因素和多因素分析显示,多发卢戈氏染色缺失(LVLs)与 SPM 有一定相关性(p=0.077,风险比[HR]4.43,95%置信区间[CI]:0.91-6.50),而同时性 ESCC 是第二原发 LC 发病的独立危险因素(p=0.037,HR 3.51,95% CI:1.08-11.41)。
ESCC 根治性切除后,必须考虑到不能通过 EGD 检测到的 SPM,如 LC。对于多发 LVLs 或同时性 ESCC 患者,我们建议通过 EGD 和计算机断层扫描进行严格筛查,以早期发现 SPM。